ADCT
ADC Therapeutics Delivers Strong Q2 Performance, Setting the Stage for Exciting Future Developments
ADC Therapeutics (ADC), a biopharmaceutical company dedicated to improving treatment outcomes for patients with complex and life-threatening cancers, has released its Q2 2026 financial results, showcasing a promising commercial performance of ZYNLONTA in the second quarter. According to Ameet Mallik, ADC's CEO, "ZYNLONTA's commercial performance